W. R. Berkley Corporation filed an amended Schedule 13G/A regarding its position in Aimei Health Technology Co., Ltd, whose securities are ordinary shares with par value $0.0001 per share, CUSIP G01341109.
The filing states that W. R. Berkley Corporation, including subsidiary Berkley Insurance Company, beneficially owns 0 shares of Aimei Health Technology and holds 0.0% of the class. It reports no sole or shared voting or dispositive power over any shares, indicating ownership of five percent or less of the class. The certification is signed by Executive Vice President and Chief Financial Officer, and by Executive Vice President and Treasurer.
Aimei Health Technology Co., Ltd. has terminated its planned business combination with United Hydrogen Group Inc. and related Cayman entities. The company sent a termination notice on July 7, 2026 under Section 9.1(b) of the Business Combination Agreement after the deal failed to close by the applicable outside date.
As a result, the Business Combination Agreement, originally signed on June 19, 2024 and amended on June 6, 2025, is no longer in effect and the proposed transaction will not be consummated. Aimei’s CEO stated the company remains confident in finding a compelling future transaction.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from July 6, 2026 to August 6, 2026. To do this, the company deposited $34,330.96 into its trust account for public shareholders.
The deposit equals the lesser of $80,000 for all outstanding public shares or $0.033 per public share for the month and represents the twentieth permitted extension. This amount is funded by an unsecured, non‑interest‑bearing promissory note to Aimei Health Ltd, which may be converted into private units at $10.00 per unit immediately before closing the planned business combination with United Hydrogen.
Aimei Health Technology Co., Ltd. director Daniel Veikko Polvi filed an initial Form 3, which is a statement of beneficial ownership for insiders. The filing shows no reportable transactions, with zero shares reported as bought, sold, or otherwise transacted in this excerpt.
Aimei Health Technology Co., Ltd. reports a board change. On June 24, 2026, director Julianne Huh resigned for personal reasons, with no disagreement on the company’s operations, policies, or practices. She confirmed all compensation has been paid and released the company from any related claims.
On June 29, 2026, the board appointed Daniel Veikko Polvi as a new director. He holds an MBA from Norwegian Business School and has served since May 2019 as managing director of Shearwater Limited, providing business management and strategic consulting services to international corporations. The company states there are no family relationships or related-party transactions requiring disclosure.
Aimei Health Technology Co., Ltd. reported Q1 2026 results as a SPAC still seeking to close its initial business combination. For the three months ended March 31, 2026, it recorded net income of $45,440, driven by $107,424 of interest on cash held in the Trust Account and offset by $61,984 of general, administrative and operational costs.
As of March 31, 2026, cash in the operating account was $18,516 with $12,276,196 held in the Trust Account and a working capital deficit of about $3,499,377. A total of 1,040,332 ordinary shares were classified as subject to possible redemption at a redemption value of $11.80 per share, alongside 2,126,000 non-redeemable ordinary shares.
The company has a pending Business Combination Agreement with United Hydrogen and notes that completion remains subject to conditions, including China Securities Regulatory Commission approval. Management discloses substantial doubt about its ability to continue as a going concern if a business combination is not completed by the July 6, 2026 combination deadline.
Aimei Health Technology Co., Ltd deposited an Extension Payment of $34,330.96 into its trust account to extend the deadline to complete its initial business combination by one month, moving the Termination Date from June 6, 2026 to July 6, 2026.
To fund this nineteenth extension, the company issued an unsecured promissory note dated June 4, 2026 to its sponsor Aimei Health Ltd and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and is due upon completion of the planned business combination with United Hydrogen, and the payees may optionally convert the principal into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd received a Nasdaq deficiency notice on May 19, 2026 because it did not file its Form 10-Q for the quarter ended March 31, 2026, which was due May 15, 2026. This means the company is currently out of compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic SEC reports.
The notice does not immediately affect the listing or trading of Aimei’s ordinary shares, rights, or units on Nasdaq. The company has 60 calendar days from the notice date to either file the missing quarterly report or submit a compliance plan, and could receive up to 180 calendar days from the report’s due date if Nasdaq accepts its plan. Aimei states it is working diligently to complete the filing and expects to regain compliance.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from May 6, 2026 to June 6, 2026. To fund this extension, the company deposited an Extension Payment of $34,330.96 into its trust account for public shareholders.
In connection with this move, Aimei Health issued a zero‑interest Promissory Note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note is due upon completion of the business combination with United Hydrogen and can be converted into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd., a Cayman Islands special purpose acquisition company listed on Nasdaq as AFJK, reports on its blank-check operations for the year ended December 31, 2025 and its efforts to complete an initial business combination.
The SPAC raised $69,690,000 into a U.S. trust account from its December 2023 IPO and concurrent private placement, after selling 6,900,000 public units at $10.00 each and 332,000 private units. It has been granted up to 36 months from the IPO closing to complete a business combination, with monthly extension loans funded by its sponsor and United Hydrogen.
Aimei has signed a definitive Business Combination Agreement with United Hydrogen Group Inc., whose operations are conducted through PRC subsidiaries, and obtained shareholder approval in November 2025. Closing remains subject to multiple conditions, including Nasdaq listing standards, minimum net tangible assets, and completion of a PRC CSRC filing by United Hydrogen under the Trial Measures for overseas offerings, which is under review.
The filing highlights significant legal and operational risks if the combined company’s main operations are in China, including evolving CSRC and cybersecurity oversight, foreign exchange controls, dividend restrictions, and the possibility that PRC authorities could delay, condition, or restrict offshore listings or capital flows, potentially affecting the value and liquidity of AFJK’s ordinary shares.